Omega Fund VI, L.P. - 12 Oct 2021 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Reporting relationship: Former 10% owner
Issuer ticker: N/A
Reported as of: 12 Oct 2021
Net transaction value: +$3,000,000
SEC form: 4
Accepted by SEC: 14 Oct 2021, 16:40:04 UTC
Prior SEC filing: 06 Oct 2021
Next SEC filing: 02 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Anne-Mari Paster, as an authorized signatory of each Reporting Person

Key filing fact

Omega Fund VI, L.P. filed Form 4 for Theseus Pharmaceuticals, Inc. on 14 Oct 2021.

Key facts

This page summarizes Omega Fund VI, L.P.'s Form 4 filing for Theseus Pharmaceuticals, Inc..
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Oct 2021, 16:40.

Change

Previous filing in this sequence was filed on 06 Oct 2021.
Current net transaction value: +$3,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

THRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +523,979
Change %
Price
Shares after: 523,979
Date: 12 Oct 2021
Ownership: Direct
Footnotes: F1, F2, F3

THRX transaction

Common Stock

Purchase

Transaction value: $3,000,000
Shares: +187,500
Change %: +36%
Price: $16.00
Shares after: 711,479
Date: 12 Oct 2021
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

THRX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -693,152
Change %: -100%
Price
Shares after: 0
Date: 12 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 523,979
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Omega Fund VI, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Omega Fund VI, L.P. ("Omega VI") held 693,152 shares of the Issuer's Series B Preferred Stock. On October 12, 2021, the Series B Preferred Stock automatically converted into 523,979 shares of the Issuer's Common Stock on a 1-for-1.32286 reverse split basis, immediately prior to and in connection with the closing of a public offering of the Issuer's securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") and without payment of further consideration.

Footnote F2

The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI.

Footnote F3

As of October 12, 2021 and after giving effect to the transactions reported above, Omega VI holds less than 10% of the outstanding shares of the Issuer's Common Stock.